BioSpace News Archive

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in clinical trial of the Company’s TYK2 JH2 allosteric inhibitor ICP-488 in China.

Coherus BioSciences, Inc., announced that effective August 1, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 250,000 shares of the common stock of the Company to two newly hired employees with a per share exercise price of $9.16, the closing trading price on the grant date.

GreenLight Biosciences and Samsung Biologics announced the successful completion of the first commercial-scale engineering run for the companies’ mRNA production partnership.

BrainCheck Inc., developer of an innovative digital cognitive assessment and care platform, announced an Investigator Initiated Research Grant Program to help fund research for evaluation, diagnosis, treatment and care for brain related disease.

Renegade.bio, an LGBTQ-owned public benefit corporation, announced today that it has begun processing highly sensitive and accurate, polymerase chain reaction (PCR) monkeypox tests for San Francisco and California at large, delivering test results in 24 hours through partnerships with surrounding clinics and hospitals.

BioInvent International AB announces treatment of the first patient in a Phase 1/2a trial of its second anti-FcyRIIB antibody BI-1607 in combination with trastuzumab in HER2+ solid tumors.

SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the addition of another site of excellence, the Yale Child Study Center at Yale University, to its Phase IIb clinical trial for SCI-110 in patients suffering from Tourette Syndrome (“TS”).

Enteral feeding is the delivery of nutrients directly into the digestive tract through a feeding tube.

ValnevaSE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today confirms the signing of the amendment to its Advance Purchase Agreement (APA)1 with the European Commission (EC), following expiration of the Member States’ opt-out period, as announced by the Company on July 20, 2022.

Truepic, the leader in digital image provenance and authenticity, will work with DePuy Synthes Canada* by integrating the Truepic Vision platform seamlessly into their operations process.